Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
Lucid Diagnostics (LUCD) announces expansion of its direct contracting initiative to drive near-term revenue for its EsoGuard® Esophageal DNA Test. The company is focusing on three main programs: fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets. To support these initiatives, Lucid has hired two experienced professionals from GRAIL, Inc. The company recently completed its first major directly-contracted testing event with Fort Worth Fire Department, where 200 firefighters received EsoGuard testing. The expansion targets self-insured entities, concierge medicine practices, and employer-funded health plans through strategic partnerships and broker networks.
Lucid Diagnostics (LUCD) annuncia l'espansione della sua iniziativa di contratto diretto per aumentare le entrate a breve termine per il suo EsoGuard® Test del DNA Esofageo. L'azienda si concentra su tre programmi principali: eventi di test precoci #CheckYourFoodTube completamente contrattati, medicina concierge e mercati dei datori di lavoro. Per supportare queste iniziative, Lucid ha assunto due professionisti esperti provenienti da GRAIL, Inc. L'azienda ha recentemente completato il suo primo evento di test direttamente contrattato con il Dipartimento dei Vigili del Fuoco di Fort Worth, dove 200 pompieri hanno ricevuto il test EsoGuard. L'espansione si prefigge di raggiungere entità auto-assicurate, pratiche di medicina concierge e piani sanitari finanziati dai datori di lavoro attraverso partnership strategiche e reti di broker.
Lucid Diagnostics (LUCD) anuncia la expansión de su iniciativa de contratación directa para impulsar los ingresos a corto plazo de su EsoGuard® Prueba de ADN Esofágico. La empresa se está enfocando en tres programas principales: eventos de pruebas de precáncer #CheckYourFoodTube totalmente contratados, Medicina de Concierge y Mercados de Empleadores. Para apoyar estas iniciativas, Lucid ha contratado a dos profesionales experimentados de GRAIL, Inc. La compañía completó recientemente su primer evento de pruebas directamente contratado con el Departamento de Bomberos de Fort Worth, donde 200 bomberos recibieron la prueba EsoGuard. La expansión está dirigida a entidades autoaseguradas, prácticas de medicina concierge y planes de salud financiados por el empleador mediante asociaciones estratégicas y redes de corredores.
Lucid Diagnostics (LUCD)는 EsoGuard® 식도 DNA 테스트의 단기 수익 증대를 위한 직접 계약 프로그램의 확장을 발표했습니다. 회사는 완전 계약된 #CheckYourFoodTube 조기 암 검사 이벤트, 컨시어지 메디슨, 고용주 시장의 세 가지 주요 프로그램에 집중하고 있습니다. 이러한 이니셔티브를 지원하기 위해 Lucid는 GRAIL, Inc. 출신의 두 명의 경험이 풍부한 전문가를 고용했습니다. 회사는 최근 포트워스 소방서와 함께 첫 번째 주요 직접 계약 테스트 이벤트를 완료하여 200명의 소방관이 EsoGuard 테스트를 받았습니다. 이번 확장은 자가 보험 단체, 컨시어지 메디슨 병원 및 고용주가 자금을 지원하는 건강 계획을 전략적 파트너십과 중개 네트워크를 통해 목표로 하고 있습니다.
Lucid Diagnostics (LUCD) annonce l'expansion de son initiative de contrat direct pour générer des revenus à court terme pour son EsoGuard® Test ADN œsophagien. L'entreprise se concentre sur trois programmes principaux : des événements de test de précancé #CheckYourFoodTube entièrement contractés, la médecine de concierge et les marchés d'employeurs. Pour soutenir ces initiatives, Lucid a recruté deux professionnels expérimentés de GRAIL, Inc. L'entreprise a récemment terminé son premier événement de test directement contracté avec le service des pompiers de Fort Worth, où 200 pompiers ont reçu le test EsoGuard. L'expansion cible les entités auto-assurées, les pratiques de médecine concierge et les plans de santé financés par les employeurs grâce à des partenariats stratégiques et des réseaux de courtiers.
Lucid Diagnostics (LUCD) kündigt die Erweiterung seiner direkten Vertragsinitiative an, um kurzfristige Einnahmen für den EsoGuard® Speiseröhren-DNA-Test zu steigern. Das Unternehmen konzentriert sich auf drei Hauptprogramme: vollständig vertraglich vereinbarte #CheckYourFoodTube-Vorveranstaltungen zur Früherkennung von Krebs, Concierge-Medizin und Arbeitgebermärkte. Um diese Initiativen zu unterstützen, hat Lucid zwei erfahrene Fachkräfte von GRAIL, Inc. eingestellt. Das Unternehmen hat kürzlich sein erstes großes direkt vertraglich vereinbartes Testereignis mit der Feuerwehr von Fort Worth abgeschlossen, bei dem 200 Feuerwehrleute den EsoGuard-Test erhalten haben. Die Expansion richtet sich an selbstversicherte Einheiten, Concierge-Medizin-Praxen und arbeitgeberfinanzierte Gesundheitspläne durch strategische Partnerschaften und Maklernetzwerke.
- Successfully executed first major contracted testing event with Fort Worth Fire Department (200 firefighters)
- Strategic expansion into contractually-guaranteed revenue streams
- Key hires from successful cancer detection firm GRAIL to drive growth
- Access to large self-insured market (over 50% of US patients)
- Still seeking traditional commercial and Medicare coverage
- Revenue generation remains in early stages
Insights
The expansion into direct contracting represents a strategic pivot for Lucid Diagnostics, targeting three key revenue channels: contracted testing events, concierge medicine and employer markets. The hiring of former GRAIL executives adds credibility to this initiative, as they bring proven experience in similar market penetration strategies.
The Fort Worth Fire Department testing event, with 200 firefighters tested, serves as a proof-of-concept for the contracted events model. The self-insured market represents over 50% of U.S. patients, offering significant growth potential. However, investors should note that while this strategy may accelerate revenue recognition through guaranteed contracts, the company's small market cap of
The focus on contractually-guaranteed revenue streams could improve predictability and reduce dependence on traditional reimbursement pathways, though success will depend heavily on the company's ability to scale these programs efficiently.
Industry veterans from leading cancer detection firm join Lucid to support expansion in fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets
"Following the recent explosion in our clinical evidence base for EsoGuard esophageal precancer testing, our team carefully explored new opportunities to expand our commercial strategy while we also seek to leverage this data to secure traditional commercial and Medicare coverage," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "With this data in hand, we are now laser-focused on translating our test volume growth into contractually-guaranteed revenue. We are confident that we can convert our growing #CheckYourFoodTube testing events into contracted events, as we recently demonstrated at the
Fully-Contracted #CheckYourFoodTube Precancer Testing Events
Lucid's #CheckYourFoodTube events program will now focus on securing agreements with self-insured entities, including employers, unions, and municipal departments to drive contractually-guaranteed revenue. Recent successes in this program include Lucid's first major directly-contracted precancer testing event, where 200 Fort Worth Fire Department firefighters received EsoGuard testing in partnership with Front Line Mobile Health. Following this initial success, the Company has designated a senior member, Erica
Concierge Medicine Program
The concierge medicine sector, which offers patients enhanced access to physicians and personalized care for an annual fee, is rapidly growing nationwide. Patients in these concierge medicine practices routinely seek access to cutting-edge technologies such as EsoGuard. Carlie Craig, Lucid's new Senior Director of Strategic Partnerships for Concierge & Executive Medicine, has extensive relationships in the concierge medicine sector and has demonstrated success at driving revenue from this sector at GRAIL and elsewhere.
Employer Markets Program
Over half of patients in
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-expands-direct-contracting-initiative-with-multiple-programs-focused-on-near-term-revenue-drivers-302296331.html
SOURCE Lucid Diagnostics
FAQ
What are the three main programs in Lucid Diagnostics' (LUCD) direct contracting initiative?
How many firefighters received EsoGuard testing at the Fort Worth Fire Department event?
What percentage of US patients are covered under self-funded plans that Lucid Diagnostics (LUCD) can target?
